pharma · Microcystic Lymphatic Malformation · Pachyonychia Congenita · PVLA
PALVELLA THERAPEUTICS
PALVELLA THERAPEUTICS, INC.
PALVELLA THERAPEUTICS is a pharma organization headquartered in Wayne, USA. It trades on NYSE under ticker PVLA. Primary therapeutic focus areas include Microcystic Lymphatic Malformation, Pachyonychia Congenita, Angioke
Wayne, USA HQ
2015 Founded
38 Employees
Public company Type
PVLA · NYSE Ticker
Company details
- Status
- Public
- HQ
- Wayne, USA
- Founded
- 2015
- Employees
- 38
- Programs
- 7
- Drugs
- 0
- Patents
- 9
QTORIN 3.9% rapamycin anhydrous gel
Phase 3 · small molecule · Pachyonychia Congenita
QTORIN 3.9% rapamycin anhydrous gel for Pachyonychia Congenita is a Phase 3 program (small_molecule) at PALVELLA THERAPEUTICS, INC. with 1 ClinicalTrials.gov record(s).
Internal code PALV-05
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- PALVELLA THERAPEUTICS, INC.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Pachyonychia Congenita
- Status
- completed
- Trials
- 1